CCR2 and metabolic dysfunction-associated steatohepatitis: Chemokines such as CCL2 and its receptor CCR2 are abnormally upregulated during NASH progression14,15, and inhibition of CCL2 and CCR2 has been shown to be a therapeutic approach for the treatment of NASH16,17.